Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | AURKA | O14965 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.38 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13559779 | 0.79 | AURKA (0.53) | MC4RBRD4ALDH1A1KDM4EAURKA | |
| SCHEMBL25910304 | 0.78 | KDM4E (0.38) | HSP90AA1HSP90AB1MC4RBRD4ALDH1A1 | |
| SCHEMBL21906804 | 0.78 | MAPT (0.46) | ALDH1A1KDM4ELMNAMAPT | |
| SCHEMBL23966768 | 0.77 | SMN1; SMN2 (0.39) | ALDH1A1 | |
| SCHEMBL23966744 | 0.77 | MC4R (0.40) | HSP90AA1HSP90AB1MC4RBRD4ALK | |
| SCHEMBL23966710 | 0.75 | KDM4E (0.46) | MC4RBRD4ALKALDH1A1KDM4E | |
| SCHEMBL21158717 | 0.72 | RET (0.40) | — | |
| SCHEMBL10271203 | 0.70 | SMN1; SMN2 (0.43) | ALDH1A1 | |
| SCHEMBL20325477 | 0.69 | AURKA (0.45) | BRD4ALDH1A1KDM4EAURKAKCNH2 | |
| SCHEMBL20325711 | 0.69 | MC4R (0.46) | MC4RALDH1A1KDM4EHRH4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | HSP90AA1 1116/4885HSP90AB1 753/4885MC4R 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.